scispace - formally typeset
Search or ask a question
Author

Jonathan Huntley

Bio: Jonathan Huntley is an academic researcher from University College London. The author has contributed to research in topics: Dementia & Cognition. The author has an hindex of 17, co-authored 48 publications receiving 4525 citations. Previous affiliations of Jonathan Huntley include University of Western Ontario & South London and Maudsley NHS Foundation Trust.


Papers
More filters
Journal ArticleDOI
TL;DR: The Lancet Commission on Dementia Prevention, Intervention, and Care met to consolidate the huge strides that have been made and the emerging knowledge as to what the authors should do to prevent and manage dementia.

3,826 citations

Journal ArticleDOI
TL;DR: Author(s): Livingston, Gill; Huntley, Jonathan; Sommerlad, Andrew ; Sommer Glad, Andrew; Ames, David; Ballard, Clive; Banerjee, Sube; Brayne, Carol; Burns, Alistair; Cohen-Mansfield, Jiska; Cooper, Claudia; Costafreda, Sergi G; Dias, Amit; Fox, Nick; Gitlin, Laura N; Howard, Robert; Kales, Helen C;

3,559 citations

Journal ArticleDOI
TL;DR: The dementia prevention potential in India, China, and this sample of Latin American countries is large, and greater than in high-income countries.

192 citations

Journal ArticleDOI
TL;DR: Using the model of WM proposed by Baddeley, neuropsychological evidence for the impairment of WM in early AD is evaluated and working memory impairment in early Alzheimer's disease is evaluated.
Abstract: Background Reports of the extent of working memory (WM) impairment in early Alzheimer's disease (AD) have been inconsistent. Using the model of WM proposed by Baddeley, neuropsychological evidence for the impairment of WM in early AD is evaluated. Method Literature searches were performed using Medline, PsycINFO and Embase databases. Individual papers were then examined for additional references not revealed by computerised searches. Results Phonological loop function is intact at the preclinical and early stages of AD, becoming more impaired as the disease progresses. In mild AD, there is impairment on tasks assessing visuospatial sketchpad (VSS) function; however, these tasks also require executive processing by the central executive system (CES). There is evidence that the CES is impaired in mild AD and may be affected in the earlier preclinical stage of the disease. Episodic buffer function may be impaired but further research is required. Conclusions Future research into central executive functioning at the earliest stages of the disease, combined with further longitudinal studies, needs to be carried out. Tasks to assess the proposed functions of the episodic buffer and specific tests of the VSS suitable for AD subjects need to be developed and validated. Learning more about these processes and how they are affected in AD is important in understanding and managing the cognitive deficits seen in the early stages of AD. Copyright © 2009 John Wiley & Sons, Ltd.

187 citations

Journal ArticleDOI
01 Apr 2015-BMJ Open
TL;DR: It is suggested that although statistically significant, CS may not lead to benefits on the ADAS-Cog in all clinical settings and difficulties with blinding of patients and use of adequate placebo controls make comparison with the results of dementia drug treatments problematic.
Abstract: Objectives To review the efficacy of cognitive interventions on improving general cognition in dementia. Method Online literature databases and trial registers, previous systematic reviews and leading journals were searched for relevant randomised controlled trials. A systematic review, random-effects meta-analyses and meta-regression were conducted. Cognitive interventions were categorised as: cognitive stimulation (CS), involving a range of social and cognitive activities to stimulate multiple cognitive domains; cognitive training (CT), involving repeated practice of standardised tasks targeting a specific cognitive function; cognitive rehabilitation (CR), which takes a person-centred approach to target impaired function; or mixed CT and stimulation (MCTS). Separate analyses were conducted for general cognitive outcome measures and for studies using ‘active’ (designed to control for non-specific therapeutic effects) and non-active (minimal or no intervention) control groups. Results 33 studies were included. Significant positive effect sizes (Hedges’ g) were found for CS with the mini-mental state examination (MMSE) (g=0.51, 95% CI 0.29 to 0.69; p Conclusions CS improves scores on MMSE and ADAS-Cog in dementia, but benefits on the ADAS-Cog are generally not clinically significant and difficulties with blinding of patients and use of adequate placebo controls make comparison with the results of dementia drug treatments problematic.

131 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: The Lancet Commission on Dementia Prevention, Intervention, and Care met to consolidate the huge strides that have been made and the emerging knowledge as to what the authors should do to prevent and manage dementia.

3,826 citations

Journal ArticleDOI
TL;DR: Author(s): Livingston, Gill; Huntley, Jonathan; Sommerlad, Andrew ; Sommer Glad, Andrew; Ames, David; Ballard, Clive; Banerjee, Sube; Brayne, Carol; Burns, Alistair; Cohen-Mansfield, Jiska; Cooper, Claudia; Costafreda, Sergi G; Dias, Amit; Fox, Nick; Gitlin, Laura N; Howard, Robert; Kales, Helen C;

3,559 citations

Journal ArticleDOI
Emma Nichols, Cassandra Szoeke, Stein Emil Vollset, Nooshin Abbasi, Foad Abd-Allah, Jemal Abdela, Miloud Taki Eddine Aichour, Rufus Akinyemi, Fares Alahdab, Solomon Weldegebreal Asgedom, Ashish Awasthi, Suzanne Barker-Collo, Bernhard T. Baune, Yannick Béjot, Abate Bekele Belachew, Derrick A Bennett, Belete Biadgo, Ali Bijani, Muhammad Shahdaat Bin Sayeed, Carol Brayne, David O. Carpenter, Félix Carvalho, Ferrán Catalá-López, Ester Cerin, Jee-Young Jasmine Choi, Anh Kim Dang, Meaza Girma Degefa, Shirin Djalalinia, Manisha Dubey, Eyasu Ejeta Duken, David Edvardsson, Matthias Endres, Sharareh Eskandarieh, André Faro, Farshad Farzadfar, Seyed-Mohammad Fereshtehnejad, Eduarda Fernandes, Irina Filip, Florian Fischer, Abadi Kahsu Gebre, Demeke Geremew, Maryam Ghasemi-Kasman, Elena V. Gnedovskaya, Rajeev Gupta, Vladimir Hachinski, Tekleberhan B. Hagos, Samer Hamidi, Graeme J. Hankey, Josep Maria Haro, Simon I. Hay, Seyed Sina Naghibi Irvani, Ravi Prakash Jha, Jost B. Jonas, Rizwan Kalani, André Karch, Amir Kasaeian, Yousef Khader, Ibrahim A Khalil, Ejaz Ahmad Khan, Tripti Khanna, Tawfik Ahmed Muthafer Khoja, Jagdish Khubchandani, Adnan Kisa, Katarzyna Kissimova-Skarbek, Mika Kivimäki, Ai Koyanagi, Kristopher J Krohn, Giancarlo Logroscino, Stefan Lorkowski, Marek Majdan, Reza Malekzadeh, Winfried März, João Massano, Getnet Mengistu, Atte Meretoja, Moslem Mohammadi, Maryam Mohammadi-Khanaposhtani, Ali H. Mokdad, Stefania Mondello, Ghobad Moradi, Gabriele Nagel, Mohsen Naghavi, Gurudatta Naik, Long H. Nguyen, Trang Huyen Nguyen, Yirga Legesse Nirayo, Molly R Nixon, Richard Ofori-Asenso, Felix Akpojene Ogbo, Andrew T Olagunju, Mayowa O. Owolabi, Songhomitra Panda-Jonas, Valéria Maria de Azeredo Passos, David M. Pereira, Gabriel David Pinilla-Monsalve, Michael A. Piradov, Constance D. Pond, Hossein Poustchi, Mostafa Qorbani, Amir Radfar, Robert C. Reiner, Stephen R. Robinson, Gholamreza Roshandel, Ali Rostami, Tom C. Russ, Perminder S. Sachdev, Hosein Safari, Saeid Safiri, Ramesh Sahathevan, Yahya Salimi, Maheswar Satpathy, Monika Sawhney, Mete Saylan, Sadaf G. Sepanlou, Azadeh Shafieesabet, Masood Ali Shaikh, Mohammad Ali Sahraian, Mika Shigematsu, Rahman Shiri, Ivy Shiue, João Pedro Silva, Mari Smith, Soheila Sobhani, Dan J. Stein, Rafael Tabarés-Seisdedos, Marcos Roberto Tovani-Palone, Bach Xuan Tran, Tung Thanh Tran, Amanuel Amanuel Tesfay Tsegay, Irfan Ullah, Narayanaswamy Venketasubramanian, Vasily Vlassov, Yuan-Pang Wang, Jordan Weiss, Ronny Westerman, Tissa Wijeratne, Grant M. A. Wyper, Yuichiro Yano, Ebrahim M Yimer, Naohiro Yonemoto, Mahmoud Yousefifard, Zoubida Zaidi, Zohreh Zare, Theo Vos, Valery L. Feigin, Christopher J L Murray 
TL;DR: The first detailed analysis of the global prevalence, mortality, and overall burden of dementia as captured by the Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study 2016 is presented, to highlight the most important messages for clinicians and neurologists.
Abstract: Background: The number of individuals living with dementia is increasing, negatively affecting families, communities, and health-care systems around the world. A successful response to these challe ...

1,790 citations

Journal ArticleDOI
03 Oct 2019-Cell
TL;DR: Recent advances in the understanding of AD pathobiology are reviewed and current treatment strategies are discussed, highlighting recent clinical trials and opportunities for developing future disease-modifying therapies.

1,369 citations